SAN

73.07

-1.78%↓

SRT3

219.3

-2.96%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.5

+1.4%↑

SAN

73.07

-1.78%↓

SRT3

219.3

-2.96%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.5

+1.4%↑

SAN

73.07

-1.78%↓

SRT3

219.3

-2.96%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.5

+1.4%↑

SAN

73.07

-1.78%↓

SRT3

219.3

-2.96%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.5

+1.4%↑

SAN

73.07

-1.78%↓

SRT3

219.3

-2.96%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.5

+1.4%↑

Home・Listă Acțiuni・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Închisă

SectorSănătate

79.55 1.66

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

79.55

Maxim

79.8

Indicatori cheie
By Trading Economics
Venit	-33M 43M
Vânzări	7.9M 218M
P/E Medie Sector	33.502 49.8
EPS	0.834
Marjă de profit	19.539
Angajați	1,950
EBITDA	-21M 63M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+29.28% upside

Dividende
By Dow Jones
Următoarele câștiguri	23 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	84M 4.1B
Deschiderea anterioară	77.89
Închiderea anterioară	79.55

Sentimentul știrilor

By Acuity

100%

333 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

51.1 / N/A Suport & Rezistență

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 mai 2026, 23:58 UTC

Câștiguri

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mai 2026, 22:57 UTC

Câștiguri

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mai 2026, 23:52 UTC

Câștiguri

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mai 2026, 23:11 UTC

Câștiguri

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mai 2026, 23:06 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mai 2026, 23:05 UTC

Câștiguri

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mai 2026, 23:04 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mai 2026, 23:03 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mai 2026, 23:03 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mai 2026, 23:02 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mai 2026, 22:42 UTC

Câștiguri

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mai 2026, 22:33 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mai 2026, 22:32 UTC

Câștiguri

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mai 2026, 22:31 UTC

Câștiguri

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mai 2026, 22:31 UTC

Câștiguri

Macquarie: 68% of FY Income From International >MQG.AU

7 mai 2026, 22:30 UTC

Câștiguri

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mai 2026, 22:30 UTC

Câștiguri

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mai 2026, 22:29 UTC

Câștiguri

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mai 2026, 22:28 UTC

Câștiguri

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mai 2026, 22:28 UTC

Câștiguri

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mai 2026, 22:27 UTC

Câștiguri

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mai 2026, 22:27 UTC

Câștiguri

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mai 2026, 22:26 UTC

Câștiguri

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mai 2026, 22:25 UTC

Câștiguri

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

29.28% sus

Prognoză pe 12 luni

Medie 86.75 EUR 29.28%

Maxim 90 EUR

Minim 83.5 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Laboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

333 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.